GRAIL Inc Reports 11% Revenue Growth, Establishes Strategic Partnerships and Expands Galleri Test Availability

GRAIL Inc reported a strong revenue growth of 11% in Q2 2025, reaching $35.5 million, with over 45,000 Galleri tests sold. The company has established partnerships with major health systems and a cash position of $606.1 million, with a cash runway extending into 2028. GRAIL Inc reported a net loss of $114 million for the quarter, but is facing challenges with achieving broad reimbursement for the Galleri test and ongoing FDA approval process.

GRAIL Inc reported a strong revenue growth of 11% in Q2 2025, reaching $35.5 million, with over 45,000 Galleri tests sold. The company has established partnerships with major health systems and a cash position of $606.1 million, with a cash runway extending into 2028. GRAIL Inc reported a net loss of $114 million for the quarter, but is facing challenges with achieving broad reimbursement for the Galleri test and ongoing FDA approval process.

The company's CEO, Robert P. Ragusa, highlighted the continued strong commercial momentum of the Galleri test, with over 45,000 tests sold in the second quarter. He emphasized the expanding partnerships with Rush University System for Health and Everlywell, which are expected to drive further growth. The company also announced the rollout of a new, automated version of the Galleri test, aimed at scaling more efficiently with future demand.

GRAIL Inc's CFO, Aaron Freidin, reported that the company's revenue for the quarter was $35.5 million, up $3.5 million or 11% as compared to the second quarter of 2024. He noted that screening revenue reached $34.4 million, while development services revenue was $1.1 million. The company's net loss for the quarter was $114 million, an improvement of 93% compared to the second quarter of 2024. Freidin also announced an updated full-year 2025 cash burn guidance of no more than $310 million.

The company's President, Joshua J. Ofman, stressed the importance of Galleri's clinical validation, referencing the PATHFINDER and NHS Galleri trials. He stated that the PATHFINDER 2 study demonstrated substantially greater additional cancer detection than the first PATHFINDER study, with high positive predictive value (PPV) and specificity.

GRAIL Inc faces challenges with achieving broad reimbursement for the Galleri test and ongoing FDA approval process. The company is working to address these issues and maintain its focus on executing regulatory and clinical milestones. Despite these challenges, the company remains confident in its product's clinical validation and growing repeat test rates, underscoring positive momentum heading into the second half of 2025.

References:
[1] https://www.marketscreener.com/news/grail-q2-loss-narrows-revenue-ticks-up-ce7c51dadf8df22d
[2] https://seekingalpha.com/news/4484350-grail-updates-2025-cash-burn-guidance-to-310m-amid-rising-galleri-test-adoption-and-expanded